Random drug screen definition

Random drug screen means drug screens that on average occur every 54 months and no less often than every 60 months.
Sample 1Sample 2Sample 3
Random drug screen means laboratory tests to detect the presence of specific drugs in body fluids and other biologic speci- mens, which are performed at irregular intervals not known in advance by the person being tested.
Sample 1Sample 2

Examples of Random drug screen in a sentence

  • Laws § 9-1-2 as to Defendants Caramadre and RadhakrishnanPlaintiffs argue that they are entitled to summary judgment on their claims in Count V that Caramadre and Radhakrishnan are civilly liable for their criminal conduct because Caramadre and Radhakrishnan have admitted to committing mail fraud, wire fraud, and identity fraud, obtaining signatures by false pretenses and forgery, and conspiring to defraud and obtain significant sums of money from insurance companies in violation of state law.

  • Random drug screen tests may be done (at the student’s expense) in Practical Nursing and Allied Health programs and must remain negative for the student to continue in the program.

  • Random drug screen and/or pill counts may be ordered by the provider at any time for any reason.

  • Section 11 gives protection to the Central Government or the authorised person or any one acting on its behalf for anything done or intended to be done under this act in good faith.

Related to Random drug screen

  • Drug sample means a unit of a prescription drug that is not intended to be sold and is intended to promote the sale of the drug.

  • Automated drug dispensing system means a mechanical or electronic system that performs

  • Analytical x-ray system means a group of components utilizing x-rays to determine the elemental composition or to examine the microstructure of materials.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Diagnostic x-ray system means an x-ray system designed for irradiation of any part of the human or animal body for the purpose of diagnosis or visualization.

  • Testing laboratory means a laboratory, facility, or entity in the state that offers or performs tests of cannabis or cannabis products and that is both of the following:

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Reference biological product means the single biological product licensed pursuant to 42 U.S.C.

  • Approved clinical trial means a phase I, phase II, phase III, or phase IV clinical trial that is conducted in relation to the prevention, detection, or treatment of cancer or other life-threatening disease or Condition and is described in any of the following:

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

  • API means American Petroleum Institute.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Brand Name Drug means a Prescription Drug that has been given a name by a manufacturer or distributor to distinguish it as produced or sold by a specific manufacturer or distributor and may be used and protected by a trademark.

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Healing arts screening means the testing of human beings using x-ray machines for the detection or evaluation of health indications when such tests are not specifically and individually ordered by a licensed practitioner of the healing arts legally authorized to prescribe such x-ray tests for the purpose of diagnosis or treatment.